Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Daiichi Sankyo’s Bid For Ranbaxy To Be Complete Soon

This article was originally published in PharmAsia News

Executive Summary

Daiichi Sankyo President Takashi Shoda announced Oct. 8 that the company's take over bid for Ranbaxy will be completed soon. According to the offer, the company plans to acquire 50.1 percent of Ranbaxy shares. Shoda stated that the company will be able to obtain the target shares through allocation of new shares to a third party and share purchase from the founding family. Ranbaxy could become a Daiichi Sankyo subsidiary as early as the end of the year. The offer received a green light Oct.3 from the Indian government and an approval from India's central bank is expected soon. (Click here for more - Japanese language



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts